Background/Aims: Chronic inflammation is a common cause of severe anemia and hyporesponsiveness to recombinant erythropoietin (EPO) therapy in maintenance hemodialysis (HD) patients. We compared various acute-phase markers and ex vivo platelet aggregation tests in relation to clinical conditions in order to find factors predictive of hemoglobin (Hb) and endogenous EPO levels in a cross-section of clinically stable HD patients. Methods: In 100 subjects, pre-HD blood levels of C-reactive protein (CRP), α1-acid-glycoprotein (AGP), α1-antitrypsin (AT), immunoglobulin (Ig) M and G (by nephelometry), antigens of endothelial von Willebrand factor (vWF), type 1 plasminogen activator inhibitor and thrombomodulin, interleukin-6, lipoprotein(a) [Lp(a)] and EPO (by ELISA), and albumin, fibrinogen, iron metabolism indices, thyroid-stimulating hormone, phosphorus, parathormone, total cholesterol, triglycerides, viral hepatitis B/C markers, liver enzyme, and aluminium were determined. Platelet aggregations in response to ristocetin (RIPA), adenosine diphosphate, and collagen were measured in whole blood (electric impedance method) and platelet-rich plasma (optical aggregometry). Results: Hb levels inversely correlated with IgM, Lp(a), soluble vWF antigen, phosphorus, and all platelet aggregations in whole blood, but not in platelet-rich plasma. HD duration and triglycerides were positive correlates of anemia. In a multivariable analysis, increased IgM, short HD duration, increased Lp(a) and enhanced whole blood RIPA (in descending order of significance) were independent predictors of low Hb levels. In 51 patients not treated with recombinant EPO, serum levels of this hormone inversely correlated with whole blood RIPA, AT, age, vWF antigen, AGP, and positively with viral hepatitis marker. Anemia and EPO levels were not affected by gender, body mass index, cause of renal failure, residual renal function, HD dose, protein catabolic rate, use of different heparins or dialysate buffers, ACE inhibitor therapy, and parathyroid or thyroid function. In additional 10 patients, single HD session resulted in an increase in IgM levels associated with a fall in total lymphocyte counts. Conclusion: Subclinical inflammation is an important determinant of anemia in maintenance HD patients. Increased serum IgM reflecting a microinflammatory effect of HD procedures, enhanced whole blood RIPA as a surrogate of vascular endothelial damage, and Lp(a) as its promoter could be markers of such impaired erythropoiesis.

Keywords:
Anemia, Endothelium, Erythropoietin, Immunoglobulin M, Inflammation, Lipoprotein(a), Platelet aggregation, Ristocetin, von Willebrand factor
1.
National Kidney Foundation – Dialysis Outcomes Quality Initiative: NKF – DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis 1997;30(suppl 3):192–240.
2.
Bárány P: Inflammation, serum C-reactive protein, and erythropoietin resistance. Nephrol Dial Transplant 2001;16:224–227.
3.
Gabay C, Kushner I: Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448–454.
4.
Bárány P, Divino Filho JC, Bergström J: High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis 1997;29:565–568.
5.
Gunnell J, Yeun JY, Depner TA, Kaysen GA: Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 1999;33:63–72.
6.
Madore F, Lowrie EG, Brugnara C, Lew NL, Lazarus JM, Bridges K, Owen WF: Anemia in hemodialysis patients: Variables affecting this outcome predictor. J Am Soc Nephrol 1997;8:1921–1927.
7.
Beguin Y, Loo M, R’Zik S, Sautois B, Lejeune F, Rorive G, Fillet G: Early prediction of response to recombinant human erythropoietin in patients with anemia of renal failure by serum transferrin receptor and fibrinogen. Blood 1993;82:2010–2016.
8.
Kario K, Matsuo T, Kobayashi H, Matsuo M, Asada R, Koide M: High lipoprotein(a) levels in chronic hemodialysis patients are closely related to the acute phase reaction. Thromb Haemost 1995;74:1020–1024.
9.
Stenvinkel P, Heimbürger O, Tuck CH, Berglund L: Apo(a)-isoform size, nutritional status and inflammatory markers in chronic renal failure. Kidney Int 1998;53:1336–1342.
10.
Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C: Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999;55:648–658.
11.
Gris JC, Branger B, Vecina F, al Sabadani B, Fourcade J, Schved JF: Increased cardiovascular risk factors and features of endothelial activation and dysfunction in dialyzed uremic patients. Kidney Int 1994;446:807–813.
12.
Borawski J, Naumnik B, Pawlak K, Myśliwiec M: Endothelial dysfunction marker von Willebrand factor antigen in haemodialysis patients: Associations with pre-dialysis blood pressure and the acute phase response. Nephrol Dial Transplant 2001;16:1442–1447.
13.
Segarra A, Chacón P, Martinez-Eyarre C, Argelaguer X, Vila J, Ruiz P, Fort J, Bartolomé J, Camps J, Moliner F, Pelegrí A, Marco F, Olmos A, Piera L: Circulating levels of plasminogen activator inhibitor type-1, tissue plasminogen activator, and thrombomodulin in hemodialysis patients: Biochemical correlations and role as independent predictors of coronary artery stenosis. J Am Soc Nephrol 2001;12:1255–1261.
14.
Borawski J, Rydzewski A, Mazerska M, Kalinowski M, Pawlak K, Myśliwiec M: Inverse relationships between haemoglobin and ristocetin-induced platelet aggregation in haemodialysis patients under erythropoietin therapy. Nephrol Dial Transplant 1996;11:2444–2448.
15.
Borawski J, Pawlak K, Myśliwiec M: Variables affecting hemoglobin level in hemodialysis patients (abstract). Nephrol Dial Transplant 1999;14:A252.
16.
Kirby EP, Mills DCB: Methods for studying the von Willebrand factor-platelet interactions; in Colman RW, Smith JB (eds): Methods for Studying Platelets and Megakaryocytes: Modern Methods in Pharmacology. New York, Liss, 1987, pp 65–89.
17.
Ewenstein BM: Vascular biology of von Willebrand factor; in Born GVR, Schwartz CJ (eds): Vascular Endothelium: Physiology, Pathology, and Therapeutic Opportunities. Stuttgart, Schattauer, 1997, pp 107–123.
18.
Borawski J, Pawlak K, Myśliwiec M: Comparison of different assays for von Willebrand factor in hemodialysis patients. Haemostasis 2000;30:308–315.
19.
Burstein SA: Cytokines, platelet production and hemostasis. Platelets 1997;8:93–104.
20.
Besarab A, Keiser JW, Frinak S: A study of parenteral iron regimens in hemodialysis patients. Am J Kidney Dis 1999;34:21–28.
21.
Wilsoncroft PS, Lofts FJ, Griffits RJ, Moore PK: The effect of 6-oxoPGE1 on human platelet aggregation in whole blood in vitro. J Pharm Pharmacol 1985;371:139–141.
22.
Born GVR: Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962;194:927–929.
23.
Altmann P: Aluminium toxicity in dialysis patients: No evidence for a threshold serum aluminium concentration. Nephrol Dial Transplant 1993;8(suppl 1):254–234.
24.
Schaefer RM, Paczek L, Berthold G, Gilge U, Heidland A: Improved immunoglobulin production in dialysis patients treated with recombinant erythropoietin. Int J Artif Organs 1992;15:204–208.
25.
Pereira BJG, Cheung AK: Complications of bioincompatibility of hemodialysis membranes; in Lameire N, Mehta RL (eds): Complications of Dialysis. New York, Marcel Dekker, 2000, pp 41–69.
26.
Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, Pober JS, Wick TM, Konkle BA, Schwartz BS, Barnathan ES, McCrae KR, Hug BA, Schmidt A-M, Stern DM: Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998;91:3527–3561.
27.
Borawski J, Naumnik B, Pawlak K, Myśliwiec M: Soluble thrombomodulin is associated with viral hepatitis, blood pressure, and medications in haemodialysis patients. Nephrol Dial Transplant 2001;16:787–793.
28.
Galle J, Heermeier K, Wanner C: Atherogenic lipoproteins, oxidative stress, and cell deaths. Kidney Int 1999;71(suppl):62–65.
29.
Miles LA, Fless G, Levin EG, Scanu AM, Plow EF: A potential basis for thrombotic risks associated with lipoprotein(a). Nature 1989;339:301–303.
30.
Kronenberg F, Trenkwalder E, Kronenberg MF, König P, Utermann G, Dieplinger H: Influence of hematocrit on the measurement of lipoproteins demonstrated by the example of lipoprotein(a). Kidney Int 1998;54:1385–1389.
31.
Bologa RM, Levine DM, Parker TS, Cheigh JS, Serur D, Stenzel K, Rubin AL: Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia and mortality in hemodialysis patients. Am J Kidney Dis 1998;32:107–114.
32.
Irish A: Cardiovascular disease, fibrinogen and the acute phase response associations with lipids and blood pressure in patients with chronic renal disease. Atherosclerosis 1998;137:133–139.
33.
Irish A: Plasminogen activator inhibitor-1 activity in chronic renal disease and dialysis. Metabolism 1997;46:35–40.
34.
Goicoechea M, Martin J, de Sequera P, Quiroga JA, Ortiz A, Carreno V, Caramelo C: Role of cytokines in the response to erythropoietin in hemodialysis patients. Kidney Int 1998;54:1337–1343.
35.
Sitter T, Bergner A, Schiffl H: Dialysate related cytokine induction and response to recombinant erythropoietin in haemodialysis patients. Nephrol Dial Transplant 2000;15:1207–1211.
36.
Allen DA, Breen C, Yaqoob MM, Macdougall IC: Inhibition of CFU-E colony formation in uremic patients with inflammatory disease: Role of INF-gamma and TNF-alpha. J Invest Med 1999;47:204–211.
37.
Fleck A, Myers MA: Diagnostic and prognostic significance of the acute-phase proteins; in Gordon AH, Koj A (eds): The Acute-Phase Response to Injury and Infection. Amsterdam, Elsevier, 1985, pp 249–271.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.